{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:44:58Z","timestamp":1789469098828,"version":"build-2803163510"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Membranous nephropathy (MN) arises from autoantibody-mediated attack on podocyte antigens, with immune deposits forming subepithelially at the glomerular basement membrane to trigger complement activation and subsequent podocyte damage, eventually manifesting as proteinuria. Traditional therapy hinges on nonspecific immunosuppression, which is characterized by modest effectiveness and a substantial side-effect profile. In recent years, CD20-targeting monoclonal antibodies, most notably rituximab (RTX), have curtailed autoantibody production through peripheral B-cell depletion and consequently emerged as a first-line treatment option for patients at intermediate-to-high risk. However, a considerable proportion of patients still show no initial response or later relapse. Resistance mechanisms are heterogeneous, encompassing Fc receptor polymorphisms, plasma cell longevity, and anti-RTX antibody formation. To address these hurdles, novel biologics that target the BAFF\/APRIL signaling axis, CD38-positive plasma cells, and the complement cascade have entered the clinical arena, further broadening the immunotherapeutic landscape for MN. In parallel, as our understanding of immune memory and autoantibody-generating cells continues to expand, a so-called \u201cimmune reset\u201d approach is gaining traction, with its core rationale being the restoration of a robust yet self-tolerant immune system. This review charts the progression of MN therapies, from CD20 monoclonal antibodies and their optimized use, through novel biologics, to vaccine-based strategies that target autoantibody-specific B or T cells (including CAAR-T, Treg therapies, B-cell epitope vaccines, and T-cell vaccines). We further consider their theoretical promise for inducing antigen-specific immune tolerance and the barriers to clinical implementation.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1955727","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:36:22Z","timestamp":1789464982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy of membranous nephropathy: strategic evolution from CD20 monoclonal antibodies to future vaccines"],"prefix":"10.3389","volume":"17","author":[{"given":"Kena","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, China"]},{"name":"Department of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaizhi","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Lin","sequence":"additional","affiliation":[{"name":"Ningbo Research Institute of Chinese Medicine, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1515\/jtim-2025-0022","article-title":"Benzo[b]fluoranthene is involved in idiopathic membranous nephropathy by inducing podocyte injury","volume":"13","author":"Yin","year":"2025","journal-title":"J Trans Internal Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/IMNA-D-23-00014","article-title":"Diagnosis and treatment of membranous nephropathy in integrative medicine","volume":"11","author":"Bi","year":"2024","journal-title":"Integr Med Nephrol Andrology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/jci85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/IMNA-D-24-00045","article-title":"Advances in the treatment of refractory membranous nephropathy with integrative medicine","volume":"12","author":"Li","year":"2025","journal-title":"Integr Med Nephrol and Andrology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/IMNA-D-25-00007","article-title":"Gut microbiota and membranous nephropathy: novel molecular mechanisms and natural product therapeutic strategies","volume":"12","author":"Zhao","year":"2025","journal-title":"Integr Med Nephrol Andrology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae243","article-title":"Therapeutic targets in membranous nephropathy: plasma cells and complement","volume":"17","author":"Tomas","year":"2024","journal-title":"Clin Kidney J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/IMNA-D-25-00020","article-title":"Traditional Chinese medicine as a promising therapy for patients with membranous nephropathy","volume":"12","author":"Jin","year":"2025","journal-title":"Integr Med Nephrol Andrology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.06.018","article-title":"Phase 1b\/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy","volume":"9","author":"Rovin","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ndt\/gfz086","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","volume":"35","author":"Barrett","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8483650","article-title":"Serum levels of BAFF and APRIL predict clinical response in anti-PLA2R-positive primary membranous nephropathy","volume":"2019","author":"Netti","year":"2019","journal-title":"J Immunol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1804416","article-title":"Immune podocyte injury in autoimmune glomerular diseases","volume":"17","author":"Zhu","year":"2026","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108361","article-title":"Common innate pathways to autoimmune disease","volume":"212","author":"Langan","year":"2020","journal-title":"Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s0952-7915(98)80162-3","article-title":"Long-lived plasma cells: a mechanism for maintaining persistent antibody production","volume":"10","author":"Slifka","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112769","article-title":"B cell dysregulation and depletion therapy in primary membranous nephropathy: prospects and potential challenges","volume":"140","author":"Wu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.suppl_1.10","article-title":"Pathogenesis of glomerular damage in glomerulonephritis","author":"Couser","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.semnephrol.2013.08.009","article-title":"Complement-mediated cellular injury","volume":"33","author":"Takano","year":"2013","journal-title":"Semin Nephrol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e328345848b","article-title":"Complement and glomerular disease: new insights","volume":"20","author":"Pickering","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2020.99899","article-title":"Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis","volume":"19","author":"Zhong","year":"2023","journal-title":"Arch Med Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad225","article-title":"Membranous nephropathy treatment standard","volume":"39","author":"Radhakrishnan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2602678","article-title":"Obinutuzumab or tacrolimus in primary membranous nephropathy","author":"Fervenza","year":"2026","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf039","article-title":"The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Kidney J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.04.059","article-title":"Anti-rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy","volume":"10","author":"Allinovi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.08.036","article-title":"Plasma cell-directed rescue with bortezomib in refractory antiphospholipase A2 receptor-positive membranous nephropathy","volume":"10","author":"Ayub","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103837","article-title":"Dual B-cell targeting in systemic lupus erythematosus: the role of combined and sequential therapy with rituximab and belimumab","volume":"24","author":"Frade-Sosa","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1571616","article-title":"Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review","volume":"12","author":"Chen","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.10.029","article-title":"Povetacicept for IgA nephropathy and primary membranous nephropathy","volume":"11","author":"Madan","year":"2026","journal-title":"Kidney Int Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2478\/jtim-2023-0136","article-title":"Impacts of cryopreservation on phenotype and functionality of mononuclear cells in peripheral blood and ascites","volume":"12","author":"Zhang","year":"2024","journal-title":"J Transl Int Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological Malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"10.1681\/ASN.2025n1643pe1639p","DOI":"10.1681\/ASN.2025n43pe39p","article-title":"Daratumumab in refractory membranous nephropathy: a report of four cases: TH-PO0773","volume":"36","author":"Bilen","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2026.106468","article-title":"Prospective cohort study of felzartamab in rituximab-resistant primary membranous nephropathy","volume":"11","author":"Trillini","year":"2026","journal-title":"Kidney Int Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.kint.2021.03.010","article-title":"Complement in membranous nephropathy: what we thought we knew and what we really know","volume":"100","author":"Cravedi","year":"2021","journal-title":"Kidney Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000038990","article-title":"A review of progress on complement and primary membranous nephropathy","volume":"103","author":"Yu","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2608684","article-title":"Retraction: Jayne DRW et\u00a0al. Avacopan for the treatment of ANCA-associated vasculitis, N Engl J Med 2021;384:599-609","author":"Rubin","year":"2026","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1159\/000551965","article-title":"New anticomplement drugs in nephrology: mechanism and indication","volume":"51","author":"Macci\u00f2","year":"2026","journal-title":"Kidney Blood Press Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27083466","article-title":"Complement dysregulation in kidney diseases: mechanisms, biomarkers, and emerging targeted therapies","volume":"27","author":"Jesio\u0142owski","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.kint.2025.09.028","article-title":"Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells","volume":"109","author":"Altun","year":"2026","journal-title":"Kidney Int"},{"key":"B51","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00428-024-03921-6","article-title":"Clinicopathological characteristics of neural epidermal growth factor-like 1 protein-associated membranous glomerulonephritis","volume":"486","author":"Hyodo","year":"2025","journal-title":"Virchows Arch"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1562662","article-title":"Chimeric autoantibody receptor T cells specifically eliminate Graves' Disease autoreactive B cells","volume":"16","author":"Cheever","year":"2025","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00375.x","article-title":"Abatacept, a novel CD80\/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis","volume":"104","author":"Korhonen","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf030","article-title":"T cell costimulatory blockade ameliorates induction of experimental membranous nephropathy potentially through T-helper 17 cell suppression in the kidney","volume":"40","author":"Chung","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.08.013","article-title":"Randomized clinical trial design to assess abatacept in resistant nephrotic syndrome","volume":"3","author":"Trachtman","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1-positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155452","article-title":"Altered Th17\/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy","volume":"141","author":"Motavalli","year":"2021","journal-title":"Cytokine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12882-021-02423-w","article-title":"Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature","volume":"22","author":"Saiki","year":"2021","journal-title":"BMC Nephrol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574997","article-title":"Th17-immune response in patients with membranous nephropathy is associated with thrombosis and relapses","volume":"11","author":"Cremoni","year":"2020","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.789713","article-title":"Therapies for membranous nephropathy: A tale from the old and new millennia","volume":"13","author":"Scolari","year":"2022","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1515\/jtim-2025-0004","article-title":"Targeting regulated cell death: Apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity","volume":"13","author":"Guo","year":"2025","journal-title":"J Transl Int Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103257","article-title":"Research advances on targeted-Treg therapies on immune-mediated kidney diseases","volume":"22","author":"Li","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1509956","article-title":"From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases","volume":"15","author":"Bulliard","year":"2024","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.03.017","article-title":"Preclinical efficacy and safety assessment of engineered regulatory T cells for treatment of IPEX and other autoimmune disorders","volume":"34","author":"Honaker","year":"2026","journal-title":"Mol Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003500","article-title":"Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study","volume":"10","author":"Barde","year":"2024","journal-title":"RMD Open"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-72245-7","article-title":"Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial","volume":"17","author":"Zhang","year":"2026","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41584-024-01201-w","article-title":"Antigen-specific immunotherapies for autoimmune disease","volume":"21","author":"Buckner","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115140","article-title":"Vaccines for immune tolerance against autoimmune disease","volume":"203","author":"Kim","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00437.2004","article-title":"Experimental membranous nephropathy redux","volume":"289","author":"Cybulsky","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.374","article-title":"DNA vaccine encoding CD40 targeted to dendritic cells in situ prevents the development of Heymann nephritis in rats","volume":"83","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202209119","article-title":"Structure of PLA2R reveals presentation of the dominant membranous nephropathy epitope and an immunogenic patch","volume":"119","author":"Fresquet","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1685738","article-title":"Clinical study of PLA2R epitope spreading for predicting proteinuria remission in primary membranous nephropathy","volume":"16","author":"Cheng","year":"2025","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080815","article-title":"Vaccinations and autoimmune diseases","volume":"9","author":"Olivieri","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13111112","article-title":"Vaccine-associated autoimmunity: from clinical signals to immune pathways","volume":"13","author":"Peng","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/bf00195293","article-title":"Immunoregulation: studies of physiological and therapeutic autoreactivity by T cell vaccination","volume":"14","author":"Lohse","year":"1992","journal-title":"Springer Semin Immunopathol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/nep.70005","article-title":"CD8(+) regulatory T cells induced by peptide vaccination ameliorates experimental model of membranous nephropathy","volume":"30","author":"Chung","year":"2025","journal-title":"Nephrol (Carlton)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2011090914","article-title":"CD8+ regulatory T cells induced by T cell vaccination protect against autoimmune nephritis","volume":"23","author":"Wang","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B82","article-title":"Specificity and cross-reactive idiotypes of anti-gp330 autoantibodies in active Heymann nephritis","volume":"70","author":"Specht Grijp-Glandorf","year":"1990","journal-title":"Immunology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.9.4824","article-title":"DNA vaccination against specific pathogenic TCRs reduces proteinuria in active Heymann nephritis by inducing specific autoantibodies","volume":"171","author":"Wu","year":"2003","journal-title":"J Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp2407","article-title":"Disease diagnostics using machine learning of B cell and T cell receptor sequences","volume":"387","author":"Zaslavsky","year":"2025","journal-title":"Science"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00880-0","article-title":"mRNA vaccines take on immune tolerance","volume":"39","author":"Wardell","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.006","article-title":"Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice","volume":"62","author":"Carambia","year":"2015","journal-title":"J Hepatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-immunol-083024-030412","article-title":"CD8+ Regulatory T cells","volume":"44","author":"Vuttaradhi","year":"2026","journal-title":"Annu Rev Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00110","article-title":"Can we improve vaccine efficacy by targeting T and B cell repertoire convergence","volume":"10","author":"Fink","year":"2019","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202524097","article-title":"Nanoparticle-based tolerogenic vaccines: next-generation strategies for autoimmune and allergic disease therapies","volume":"65","author":"Nachod","year":"2026","journal-title":"Angew Chem Int Ed Engl"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20213210S130c","article-title":"Chimeric autoantibody receptor (CAAR) T cells as a precision therapy for antigen-specific B cell depletion in PLA2R membranous nephropathy: FR-OR32","volume":"32","author":"Payne","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.593288","article-title":"Autoantibodies in the diagnosis, monitoring, and treatment of membranous nephropathy","volume":"12","author":"Tesar","year":"2021","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1955727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:36:24Z","timestamp":1789464984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1955727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2026.1955727"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1955727","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1955727"}}